August 4, 2022 07:28 AM EDTUpdated 08:49 AM

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition

Kyle LaHucik

Senior Reporter

While Pfizer’s $11.4 billion acquisition of Array BioPharma in the summer of 2019 was mainly focused on oncology, namely Braftovi and Mektovi, there were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug

J&J looks at potential bid for Intra-Cellular — report

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Post-Hoc: Big Pharma is losing the AI talent war

Exclusive: Bucking gene editing downturn, Tune raises $175M to bring epigenetic editing to clinic

Chasing the next wave of obesity drugs, Metsera files for an IPO

Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition